secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2022-04-26T23:59:59+00:00
Accession:  0001193125-22-118940
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Pharmaceuticals appoints Frank Karbe to board of directors
------------------------------------------------------------------

- Frank Karbe appointed as Class II director effective April 25, 2022; will serve on audit and compensation committees.
- Karbe previously served as President and CFO of Myovant Sciences, and EVP and CFO of Exelixis.
- Received option to purchase 20,000 shares of common stock with three-year vesting, plus cash compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522118940/0001193125-22-118940-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522118940/d622345d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-118940

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer